Clinical trialNCT02638909TerminatedPhase 2Interventional

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

SponsorCriterium, Inc.Enrollment4CholangiocarcinomaColorectal AdenocarcinomaEsophageal AdenocarcinomaGastric AdenocarcinomaHepatocellular AdenocarcinomaPancreatic Adenocarcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The available data indicate that Ceritinib has substantial anti-tumor activity in patients with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC). This trial will investigate the potential of Ceritinib in patients with advanced gastrointestinal malignancies with ALK and ROA1 rearrangement, and for whom there is no available therapeutic option.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Christopher Lieu, MD
Criterium Inc., d.b.a. Academic GI Cancer Consortium (AGICC)
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Yale University, Yale Cancer Center
New Haven, Connecticut, United States
Laura & Isaac Permutter Cancer Center at Nyu Langone
New York, New York, United States
the Ohio State University, James Cancer Hospital
Columbus, Ohio, United States
Swedish Cancer Institute
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ceritinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2015
Primary completion: 29 Mar 2018
Completion: 29 Mar 2018
Last update posted: 2 Apr 2018
Registered enrollment: 4
Registry id: NCT02638909

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.